Q1FY22 Result Preview - Healthcare - ICICI Direct

Lower base and a revival in domestic formulations is likely to drive overall sales. On the other hand, despite a favourable base in some select stocks, US formulations growth is expected to remain subdued amid lack of meaningful launches, price erosion and currency headwinds. The I-direct healthcare universe (12 coverage companies) is expected to post decent YoY growth of 11.4% to ~Rs. 44497 crore led by strong growth in domestic formulations being partly offset by slow growth in the US. Domestic growth is expected to be led by lower base, recovery in acute segment growth and Covid-related product sales.

For details, click on the link below: Link to the report

Source : Equity Bulls

Keywords